A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism

Inclusion criteria

• ✓. If not receiving thyroid hormone replacement therapy, the participant has a serum thyroid stimulating hormone (TSH) level within normal laboratory limits at screening.
• ✓. If receiving thyroid hormone replacement therapy, the dose must have been stable for at least 3 months prior to screening and serum TSH level within the reference range for the laboratory.
• ✓. Hypocalcemia (albumin-corrected serum calcium \<8.0 mg/dL) or
• ✓. Hypercalciuria (urine calcium \[mg/dL\]/creatinine \[mg/dL\] ratio \>0.4 or 24 hour urine calcium excretion \>7.5 millimoles (mmol) \[300 milligram {mg}\]/24 hours in men and \>6.25 millimoles (mmol) \[250 mg\]/24 hours in women) or,
• ✓. Symptoms of hypoparathyroidism.